

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2579722

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KYOWA HAKKO KIRIN CO., LTD.	06/30/2010
RECEIVING PARTY DATA	
Name:	ARGOS THERAPEUTICS, INC.
Street Address:	4233 TECHNOLOGY DRIVE
City:	DURHAM
State/Country:	NORTH CAROLINA
Postal Code:	27704
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13941627
CORRESPONDENCE DATA	
Fax Number:	(919)287-6302
Email:	aclark@argostherapeutics.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	ARGOS THERAPEUTICS, INC.
Address Line 1:	4233 TECHNOLOGY DRIVE
Address Line 4:	DURHAM, NORTH CAROLINA 27704
ATTORNEY DOCKET NUMBER:	ARG030CIPDV
NAME OF SUBMITTER:	ALIDA M. CLARK
Signature:	/Alida M. Clark/
Date:	10/16/2013
Total Attachments: 6 source=KHK to Argos Assignment#page1.tif	

CH \$40.00 13941627

source=KHK to Argos Assignment#page2.tif
source=KHK to Argos Assignment#page3.tif
source=KHK to Argos Assignment#page4.tif
source=KHK to Argos Assignment#page5.tif
source=KHK to Argos Assignment#page6.tif

PATENT RIGHTS TRANSFER AGREEMENT

THIS AGREEMENT ("This Agreement") is entered into this 30th day of June 2010 by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 4233 Technology Drive, Durham, NC 27704 ("Argos") and Kyowa Hakko Kirin Co., Ltd. (formerly known as Kirin Brewery Company Limited; Kirin Beer Kabushiki Kaisha; Kirin Pharma Co. Ltd.; and Kirin Pharma Kabushiki Kaisha), a Japanese corporation having its principal office at Ohtemachi Building SF, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo Japan 100-8185 ("KHK").

WITNESSETH

WHEREAS, Argos and KHK were parties to that certain Collaboration and License Agreement dated June 17, 2004, as amended (the "Collaboration Agreement"), pursuant to which the parties had agreed that any patentable inventions conceived or reduced to practice in the course of the performance of the Research Program (as defined therein) shall be jointly owned;

WHEREAS, Argos and KHK are parties to that certain Collaboration Termination Agreement dated December 31, 2009 ("Termination Agreement"); pursuant to which the parties have agreed that KHK shall return to Argos its rights in certain patentable inventions conceived or reduced to practice in the course of the performance of the Research Program; wherein patent applications to said inventions have been filed with the following titles:

"Strain -Independent Amplification of Pathogens and Vaccines Thereto";

"Mature Dendritic Cell Compositions and Methods for Culturing Same";

"Devices, Systems and Related Methods Suitable for Delivery of a Liquid Medicament Stored at Cryogenic Temperatures"

"Dendritic Cell Compositions and Methods";

"Systems and Methods for Processing Samples in Closed Containers and Related Devices";

"Dendritic Cells Transiently Transfected with a Membrane Homing Polypeptide and Their Use";

"Improved Primers and Probes for the Amplification and Detection of HIV Gag, Rev and Nef Polynucleotides"; and

"Transient Expression of Immunomodulatory Polypeptides for the Prevention and Treatment of Autoimmune Disease, Allergy and Transplant Rejection"

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties agree as follows:

1. **Assignment of Patent Rights.** In accordance with the Termination Agreement, KHK does hereby sell, assign and transfer to Argos, its successors, legal representatives and assigns, the entire interest in all of KHK's right, title and interest in and to the patent applications listed in Exhibit A, all patents issued on such applications, and all patent applications and patents claiming priority thereto, including all continuations, continuations-in-part, divisions, reissues, reexaminations, renewals, extensions, supplementary protection certificates, utility models and foreign equivalents thereof. KHK hereby authorizes and requests the proper officer or agency of any and all countries to issue all letters patent(s) issuing therefrom solely in the name of Argos.


2. **Binding Effect.** This Agreement will be binding upon and will inure to the benefit of the parties, their respective heirs, representatives, successors, and assigns.

3. **Entire Agreement.** This Agreement, together with all exhibits and attachments will be deemed to express, embody and supersede all previous understandings, agreements, and commitments, whether written or oral, between the parties with respect to the subject matter hereof and to fully and finally set forth the entire agreement between the parties. All exhibits referenced herein are hereby incorporated by reference.

4. **Governing Law.** This Agreement will be governed by the substantive laws of the State of Delaware, without regard to its principles governing conflict of laws, except with respect to matters of intellectual property law which shall be determined in accordance with U.S. federal intellectual property laws.


IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the Effective Date.

ARGOS THERAPEUTICS, INC.

By: 
Name: Jeffrey Abbey
Title: President and CEO

Date: July 27, 2010

KYOWA HAKKO KIRIN CO., LTD.

By: 
Name: Masau Takayanagi
Title: Managing Officer

Date: June 30, 2010

Exhibit A

Patent Applications

ARG029 Patent Family

**"STRAIN-INDEPENDENT AMPLIFICATION OF PATHOGENS AND VACCINES
THERE TO"**

Country	Application No.	Docket No.
U.S.	60/522,310	ARG029PR
U.S.	60/665,130	ARG029PR2
PCT	PCT/US2005/032710	ARG029WO
Hong Kong	07113279.8	ARG029HK
Canada	2,577,320	ARG029CA
EPO	05797971.8	ARG029EP
Korea	10-2007-7005912	ARG029KR
Australia	2005284922	ARG029AU
Japan	2007-532416	ARG029JP
China	200580030658.6	ARG029CN
U.S.	11/662,828	ARG029US

ARG030 Patent Family

"MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING THE SAME"

Country	Application No.	Docket No.
U.S.	60/522,512	ARG030PR
Taiwan	094135203	ARG030TW
U.S.	11/246,387	ARG030
U.S.	11/400,774	ARG030CIP
PCT	PCT/US2007/08734	ARG030CIPWO
U.S.	12/226,092	ARG030CIPUS
Korea	10-2008-7024226	ARG030CIPKR
Australia	2007235227	ARG030CIPAU
Canada	2648675	ARG030CIPCA
China	200780020901.5	ARG030CIPCN
EPO	07755113.3	ARG030CIPEP
Japan	2009-504346	ARG030CIPJP
PCT	PCT/US2005/036304	ARG030WO
Korea	10-2007-7008070	ARG030KR
Australia	2005294150	ARG030AU
Japan	2007-535869	ARG030JP
China	200580033740.4	ARG030CN
EPO	05804341.5	ARG030EP
Canada	2,577,125	ARG030CA
U.S.	11/664,899	ARG030US
Hong Kong	07113385.9	ARG030HK

ARG034 Patent Family

"DEVICES, SYSTEMS AND RELATED METHODS SUITABLE FOR DELIVERY OF A LIQUID MEDICAMENT STORED AT CRYOGENIC TEMPERATURES"

Country	Application No.	Docket
Australia	2006299791	ARG034AU
Canada	2623867	ARG034CA

ARG035 Patent Family

"DENDRITIC CELL COMPOSITIONS AND METHODS"

Country	Application No.	Docket No.
India	4447/CHENP/2007	ARG035IN
China	200680011380.2	ARG035CN
Hong Kong	08101621.7	ARG035HK
Korea	10-2007-7025609	ARG035KR
Israel	185977	ARG035IL
Norway	20075166	ARG035NO
Mexico	MX/a/2007/012221	ARG035MX
Canada	2602434	ARG035CA
Australia	2006249640	ARG035AU
Singapore	200716720-8	ARG035SG

ARG036 Patent Family

"SYSTEMS AND METHODS FOR PROCESSING SAMPLES IN A CLOSED CONTAINER AND RELATED DEVICES"

Country	Application No.
US	60/760,087
PCT	PCT/US2007/001170
Australia	2007282135
Canada	2635268
China	200780002497.9
EPO	07835665.6
Japan	2008-551336
Singapore	2008-052565
Korea	10-2008-7017409
US	12/159,748
Hong Kong	09102916.8

ARG038 Patent Family

"DENDRITIC CELLS TRANSIENTLY TRANSFECTED WITH A MEMBRANE HOMING POLYPEPTIDE AND THEIR USE"

Country	Application No.	Docket No.
EPO	08110306.5	ARG038EP
US	60/775,735	ARG038PR
PCT	PCT/EP2007/051417	ARG038WO
Australia	2007217630	ARG038AU
Canada	2,642,999	ARG038CA
EPO	07728373.9	ARG038EP2
China	200780014380.6	ARG038CN
Korea	10-2008-7020421	ARG038KR
Japan	2008-555751	ARG038JP
Singapore	200805650-9	ARG038SG
US	12/223,729	ARG038US

ARG043 Patent Family

"IMPROVED PRIMERS AND PROBES FOR THE AMPLIFICATION AND DETECTION OF HIV GAG, REV AND NEF POLYNUCLEOTIDES"

Country	Application No.	Docket No.
US	60/962,510	ARG043PR
PCT	PCT/US2008/009185	ARG043WO
US	12/452,580	ARG043US

ARG046 Patent Family

"TRANSIENT EXPRESSION OF IMMUNODULATORY POLYPEPTIDES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE, ALLERGY AND TRANSPLANT REJECTION"

Country	Application No.	Docket No.
US	61/067,459	ARG046PR
PCT	PCT/US2009/001232	ARG046WO